1. Home
  2. Analysis
  3. Rozerem
  4. Gemfibrozil

Rozerem and Gemfibrozil drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Rozerem (ramelteon) and Gemfibrozil (gemfibrozil). Common drug interactions include chronic kidney disease among females and diabetic neuropathy among males.

The phase IV clinical study analyzes what interactions people have when they take Rozerem and Gemfibrozil. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Rozerem?

Rozerem has active ingredients of ramelteon. It is often used in insomnia. eHealthMe is studying from 7,539 Rozerem users. Check the latest studies of Rozerem.

What is Gemfibrozil?

Gemfibrozil has active ingredients of gemfibrozil. It is often used in high blood cholesterol. eHealthMe is studying from 18,213 Gemfibrozil users. Check the latest studies of Gemfibrozil.

On Aug, 06, 2026

20 people who take Rozerem and Gemfibrozil together, and have interactions are studied.

Rozerem and Gemfibrozil drug interactions.

What are the common drug interactions of Rozerem and Gemfibrozil, by gender? *:

female:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)
  3. Aggression
  4. Ankle fracture
  5. Anxiety
  6. Arthralgia (joint pain)
  7. Back pain
  8. Bone density decreased
  9. Bone loss
  10. Dental caries

male:

  1. Diabetic neuropathy (neuropathic disorders that are associated with diabetes mellitus)
  2. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  3. Initial insomnia (feeling of inadequate or poor-quality sleep)
  4. Injection site erythema (redness at injection site)
  5. Injection site pain
  6. Injection site swelling
  7. Injection site warmth
  8. Middle insomnia (difficulty returning to sleep after awakening either in the middle of the night)
  9. Nausea (feeling of having an urge to vomit)
  10. Pancreatitis (inflammation of pancreas)

What are the common drug interactions of Rozerem and Gemfibrozil, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  2. Chronic kidney disease
  3. Diabetic neuropathy (neuropathic disorders that are associated with diabetes mellitus)
  4. Renal failure (kidney dysfunction)
  5. Type 2 diabetes mellitus

50-59:

  1. Chronic kidney disease
  2. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  3. Constipation
  4. Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
  5. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  6. Essential hypertension (primary hypertension)
  7. Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
  8. Hepatitis c
  9. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  10. Nausea (feeling of having an urge to vomit)

60+:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)
  3. Injection site warmth
  4. Middle insomnia (difficulty returning to sleep after awakening either in the middle of the night)
  5. Poor quality sleep
  6. Renal impairment (severely reduced kidney function)
  7. Abdominal distension
  8. Anxiety
  9. Dizziness
  10. Drug ineffective

What are the existing conditions these people have? *

  1. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 30.00%
  2. Depression: 5 people, 25.00%
  3. Sleep Disorder: 4 people, 20.00%
  4. Pain: 4 people, 20.00%
  5. Chest Pain: 3 people, 15.00%
  6. Stress And Anxiety: 3 people, 15.00%
  7. Irritable Bowel Syndrome: 3 people, 15.00%
  8. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 10.00%
  9. Menopause (end of monthly cycles in women): 2 people, 10.00%
  10. Cough: 2 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Rozerem and Gemfibrozil?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Rozerem and Gemfibrozil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rozerem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Gemfibrozil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rozerem and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gemfibrozil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ramelteon and gemfibrozil (the active ingredients of Rozerem and Gemfibrozil, respectively), and Rozerem and Gemfibrozil (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.